• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFR14A filed by Biofrontera Inc.

    6/3/25 5:11:21 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BFRI alert in real time by email
    DEFR14A 1 formdefr14a.htm DEFR14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 14A INFORMATION

     

    PROXY STATEMENT

    PURSUANT TO SECTION 14(a) OF THE

    SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 1)

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

     

    ☐ Preliminary Proxy Statement
    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☒ Definitive Proxy Statement
    ☐ Definitive Additional Materials
    ☐ Soliciting Material Pursuant to Section 240.14a-12

     

    BIOFRONTERA INC.

    (Name of Registrant as Specified in Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

     

    Payment of Filing Fee (check the appropriate box):

     

    ☒ No fee required.
    ☐ Fee paid previously with preliminary materials.
    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

     

     

     

    SUPPLEMENT DATED JUNE 3, 2025

     

    TO THE PROXY STATEMENT FOR

     

    THE 2025 ANNUAL MEETING OF STOCKHOLDERS OF BIOFRONTERA INC.

     

    To Be Held on June 12, 2025

     

     

     

     

    Explanatory Note

     

    On April 30, 2025, Biofrontera Inc. (the “Company”) filed a Proxy Statement (the “Proxy Statement”) with the Securities and Exchange Commission in connection with the Company’s 2025 Annual Meeting of Stockholders to be held June 12, 2025, at 10:00 a.m., Eastern Time (the “Meeting”).

     

    After the filing of the Proxy Statement, the Company was advised that the New York Stock Exchange (“NYSE”) has determined that Proposal Nos. 2 and 3 included in the Proxy Statement are considered “routine” matters under NYSE rules, meaning that banks, brokers and other nominees have authority to vote shares held in street name on Proposal Nos. 2 and 3 without receiving voting instruction from the beneficial owner of such shares. This determination differs from the disclosure in the Proxy Statement, which indicated that only Proposal No. 4 in the Proxy Statement was a “routine” matter and, therefore, banks, brokers and other nominees would not have the authority to vote shares held in street name on Proposal Nos. 2 and 3 without receiving voting instructions from the beneficial owner of such shares. Accordingly, this supplement to the Proxy Statement is being filed to revise our initial disclosure in the Proxy Statement regarding what happens when a stockholder does not vote on Proposal Nos. 2 and 3.

     

    The answer under the heading “Questions and Answers – What happens if I do note vote?” on page 4 of the Proxy Statement is hereby amended and restated as follows:

     

      Q: What happens if I do not vote?
         
      A: Stockholder of Record: Shares Registered in Your Name
         
        If you are a stockholder of record and do not vote in person or proxy by returning a proxy card or submitting your proxy through the internet or by telephone, your shares will not be voted.

     

        Beneficial Owner: Shares Registered in the Name of Broker or Bank
         
        If you are a beneficial owner and do not instruct your broker, bank, or other agent how to vote your shares, your broker or nominee will be able to vote your shares only on proposals that are “routine” matters. At the Meeting, approval of an amendment to our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of our common stock from 35,000,000 to 70,000,000 (Proposal No. 2), approval of a proposal to adjourn the Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of Share Increase Proposal (Proposal No. 3), and the ratification of the appointment of our independent registered public accounting firm (Proposal No. 4) are each considered a “routine” matter. However, we understand that certain brokerage firms have elected not to vote even on “routine” matters without your voting instructions. If your bank, broker or other nominee has made this decision, and you do not provide voting instructions, your shares will not be voted at the Annual Meeting. Accordingly, we urge you to direct your bank, broker or other nominee how to vote by returning your voting materials as instructed or by obtaining a legal proxy from your broker or other nominee in order to vote your shares electronically at the Annual Meeting. This ensures that your shares will be voted at the Meeting in the manner you desire.

     

    Other than the revised language above, no other changes have been made to the Proxy Statement, and the Company’s Board of Directors continues to seek the vote of Company stockholders to be voted on at the Meeting as recommended in the original Proxy Statement. As a stockholder, your vote is very important, and the Board encourages you to exercise your right to vote whether or not you plan to attend the Annual Meeting.

     

    Proxies already received will continue to be voted as instructed unless otherwise revoked or changed by a subsequent proxy.

     

    EXCEPT AS DESCRIBED IN THIS SUPPLEMENT, THE INFORMATION PROVIDED IN THE PROXY STATEMENT REMAINS UNCHANGED. TO THE EXTENT THAT INFORMATION IN THIS SUPPLEMENT DIFFERS FROM OR UPDATES INFORMATION CONTAINED IN THE PROXY STATEMENT, THE INFORMATION IN THIS SUPPLEMENT IS MORE CURRENT. THE PROXY STATEMENT CONTAINS ADDITIONAL INFORMATION. THIS SUPPLEMENT SHOULD BE READ IN CONJUNCTION WITH THE PROXY STATEMENT.

     

     

     

     

    Get the next $BFRI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BFRI

    DatePrice TargetRatingAnalyst
    12/15/2021$11.00Buy
    Benchmark
    11/24/2021$20.00Buy
    Roth Capital
    More analyst ratings

    $BFRI
    Leadership Updates

    Live Leadership Updates

    See more
    • Biofrontera Inc. Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer Accounts

      WOBURN, MA / ACCESSWIRE / August 29, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announced today the appointment of Samantha (Sam) Widdicombe to the newly created position of Senior Director, Strategic Accounts and Communications. Biofrontera created this position in response to the growing demand and opportunity for specialized sales and marketing approaches resulting from an evolving landscape of medical practices consolidating into larger integrated organizations.Reporting to Mark Baldyga, Vice President of Sales and Marketing, Ms. Widdicombe joins Biofrontera with over

      8/29/23 8:00:00 AM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biofrontera Inc. Appoints Dr. Heikki Lanckriet to its Board of Directors

      WOBURN, MA / ACCESSWIRE / July 12, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces the appointment of Heikki Lanckriet, Ph.D. to its Board of Directors. Dr. Lanckriet brings to Biofrontera more than 20 years of commercial and scientific experience in the life sciences industry, along with proven success in developing high-growth technology companies.Dr. Lanckriet was nominated to Biofrontera Inc.'s Board of Directors by Biofrontera AG under the terms of the April 2023 settlement agreement between the two companies previously disclosed in the Company's Current Report o

      7/12/23 8:00:00 AM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biofrontera Inc. Announces Resignation of CEO

      Executive Chairman Hermann Luebbert to Assume CEO Responsibilities, Reaffirms the Company's Strategic Plan and 2023 Commercial GoalsWOBURN, MA / ACCESSWIRE / May 12, 2023 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces the resignation of Erica Monaco as Chief Executive Officer, which will be effective pending the completion of a near term transition of responsibilities with the Board of Directors. Hermann Luebbert, Biofrontera's Executive Chairman and founder, will assume the CEO responsibilities. Ms. Monaco intends to pursue other professional opportunities and her resignation did not res

      5/12/23 7:00:00 AM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BFRI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book

      Biofrontera received patent approval for the revised formulation of Ameluz® in April 2025, extending patent protection through to December 2043.The Orange Book is published by the U.S. Food and Drug Administration (FDA) and lists all approved prescription drug products, along with patent and exclusivity information.Inclusion signifies FDA recognition of the revised formulation's approved status and its intellectual property protection. WOBURN, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), today announced the inclusion of the patent for its propylene glycol

      6/3/25 2:30:00 PM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update

      Conference call begins at 10:00 a.m. Eastern time on Friday, May 16, 2025 WOBURN, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results for the three months ended March 31, 2025 and provided a business update. Highlights from the first quarter of 2025 and subsequent weeks included the following: Total revenues for the first quarter of 2025 were $8.6 million, a 9% increase from the same period of the prior year.Cash and cash equivalents were $1.8 million as of March 31, 2025, compared with $5.9 million on December 31, 2024.Announce

      5/15/25 5:09:00 PM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis

      The initiative is a social media challenge ahead of Global AK Awareness Day, on May 24, which supports the work of The Skin Cancer Foundation and EuromelanomaThe Hats On Challenge provides an opportunity to take part in raising awareness of AK.Actinic Keratosis (AK) is a rough, scaly patch on the skin caused by years of sun exposure. If left untreated, AK can develop into squamous cell carcinoma, a type of skin cancer. Woburn, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), and Almirall, a global pharmaceutical company dedicated to medical dermatology an

      5/1/25 2:38:00 PM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BFRI
    Financials

    Live finance-specific insights

    See more
    • Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update

      Conference call begins at 10:00 a.m. Eastern time on Friday, May 16, 2025 WOBURN, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results for the three months ended March 31, 2025 and provided a business update. Highlights from the first quarter of 2025 and subsequent weeks included the following: Total revenues for the first quarter of 2025 were $8.6 million, a 9% increase from the same period of the prior year.Cash and cash equivalents were $1.8 million as of March 31, 2025, compared with $5.9 million on December 31, 2024.Announce

      5/15/25 5:09:00 PM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update

      Conference scheduled for Friday, March 21, 2025 at 10:00 a.m. Eastern time Woburn, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today reported financial results for the three and twelve months ended December 31, 2024. Highlights from 2024 and subsequent weeks include: Reported record total revenues of $37.3 million for 2024, reflecting a 9.5% increase from $34.1 million in 2023 with Q4 2024 growing 18.5% over Q4 2023. The growth was primarily driven by increases in Ameluz® sales volume and unit price, and the successful launch of our RhodoLED® XL Lam

      3/21/25 8:00:00 AM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025

      WOBURN, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the development and commercialization of dermatological products, today announced that it will report financial results for the three and 12 months ended December 31, 2024 on Friday, March 21, 2025. The results will be released before the market opens on Friday, March 21 and the company will host a conference call on Friday, March 21 at 10:00am Eastern Time. Conference Call and Webcast Information DateFriday, March 21, 2025Time10:00 AM Eastern TimeDial In Numbers1-877-877-1275 (U.S.)1-412-858-5202 (international)WebcastFourth Quarter and FY 2024 Financial Results a

      3/11/25 10:00:00 AM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BFRI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Benchmark initiated coverage on Biofrontera with a new price target

      Benchmark initiated coverage of Biofrontera with a rating of Buy and set a new price target of $11.00

      12/15/21 6:49:18 AM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roth Capital initiated coverage on Biofrontera with a new price target

      Roth Capital initiated coverage of Biofrontera with a rating of Buy and set a new price target of $20.00

      11/24/21 8:02:09 AM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BFRI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Biofrontera Inc.

      SC 13G/A - Biofrontera Inc. (0001858685) (Subject)

      11/14/24 3:54:03 PM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Biofrontera Inc.

      SC 13G/A - Biofrontera Inc. (0001858685) (Subject)

      11/14/24 1:13:39 PM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Biofrontera Inc.

      SC 13G/A - Biofrontera Inc. (0001858685) (Subject)

      11/13/24 2:12:35 PM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BFRI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Weber Kevin Daniel

      4 - Biofrontera Inc. (0001858685) (Issuer)

      7/16/24 7:52:14 PM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Lanckriet Heikki

      4 - Biofrontera Inc. (0001858685) (Issuer)

      7/16/24 7:52:13 PM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Leffler Eugene Frederick

      4 - Biofrontera Inc. (0001858685) (Issuer)

      7/16/24 7:52:11 PM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BFRI
    SEC Filings

    See more
    • Biofrontera Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Biofrontera Inc. (0001858685) (Filer)

      6/3/25 5:15:02 PM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFR14A filed by Biofrontera Inc.

      DEFR14A - Biofrontera Inc. (0001858685) (Filer)

      6/3/25 5:11:21 PM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Biofrontera Inc.

      8-K - Biofrontera Inc. (0001858685) (Filer)

      5/23/25 4:30:14 PM ET
      $BFRI
      Biotechnology: Pharmaceutical Preparations
      Health Care